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The placenta acts as physical and immunological barrier against the transmission
of viruses and bacteria from mother to fetus. However, the specific mechanisms by
which the placenta protects the developing fetus from viral and bacterial pathogens
are poorly understood. To identify placental peptides and small proteins protecting
from viral and bacterial infections, we generated a peptide library from 10 kg placenta
by chromatographic means. Screening the resulting 250 fractions against Herpes-
Simplex-Virus 2 (HSV-2), which is rarely transmitted through the placenta, in a cell-
based system identified two adjacent fractions with significant antiviral activity. Further
rounds of chromatographic purification and anti-HSV-2 testing allowed to purify the
bioactive peptide. Mass spectrometry revealed the presence of a 36-mer derived from
the C-terminal region of the hemoglobin β subunit. The purified and corresponding
chemically synthesized peptide, termed HBB(112–147), inhibited HSV-2 infection in a
dose-dependent manner, with a mean IC50 in the median µg/ml range. Full-length
hemoglobin tetramer had no antiviral activity. HBB(112–147) did not impair infectivity by
direct targeting of the virions but prevented HSV-2 infection at the cell entry level. The
peptide was inactive against Human Immunodeficiency Virus Type 1, Rubella and Zika
virus infection, suggesting a specific anti-HSV-2 mechanism. Notably, HBB(112–147)
has previously been identified as broad-spectrum antibacterial agent. It is abundant in
placenta, reaching concentrations between 280 and 740 µg/ml, that are well sufficient to
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inhibit HSV-2 and prototype Gram-positive and -negative bacteria. We here additionally
show, that HBB(112–147) also acts potently against Pseudomonas aeruginosa strains
(including a multi-drug resistant strain) in a dose dependent manner, while full-length
hemoglobin is inactive. Interestingly, the antibacterial activity of HBB(112–147) was
increased under acidic conditions, a hallmark of infection and inflammatory conditions.
Indeed, we found that HBB(112–147) is released from the hemoglobin precursor by
Cathepsin D and Napsin A, acidic proteases highly expressed in placental and other
tissues. We propose that upon viral or bacterial infection, the abundant hemoglobin
precursor is proteolytically processed to release HBB(112–147), a broadly active
antimicrobial innate immune defense peptide.
Keywords: placenta, AMP, hemoglobin fragment, proteolytic generation, antiviral
INTRODUCTION
The placenta is a fetal organ tightly interacting with maternal
blood vessels to nourish and protect the fetus (Robbins and
Bakardjiev, 2012). Placental infections by pathogens are major
causes of disease and represent a substantial source of human
morbidity and mortality. The placenta is composed of villi that
float in maternal blood and organize the exchange of substances
between the mother and fetus. At this interface bacteria and
viruses may enter the placenta and be transmitted to the fetus.
Thus, the placenta is an important transmission site for viral
and bacterial infections, and therefore it is conceivable that this
organ evolved antiviral and antibacterial innate immune defense
mechanisms that prevent or restrict diaplacental pathogen
transmission. Indeed, only relatively few pathogens are capable of
placental and fetal infections in humans (Robbins and Bakardjiev,
2012). For example, most viral dia-placental transmissions
are caused by Cytomegalovirus, Lymphocytic choriomeningitis
virus, Parvovirus B19, Rubella Virus and Varicella zoster virus
(Robbins and Bakardjiev, 2012), but generally the frequencies
are low. More recently, it has also been shown that Zika virus
(ZIKV) may cross the placenta and infect the fetus which may
result in severe developmental defects of the fetus (Zanluca et al.,
2018). However, for the majority of viral pathogens the placenta
represents an impenetrable barrier (Robbins and Bakardjiev,
2012). For example, Herpes simplex viruses (HSV) -1 and -2
have infected billions of people. In the US, neonatal infection
with HSV occurs in 1 out of every 3200–10,000 live births and
is associated with serious morbidity and mortality, and leaves
many survivors with permanent sequelae (Brown et al., 2003;
Mahnert et al., 2007; Roberts, 2009; Flagg and Weinstock, 2011).
Interestingly, most congenital HSV infections are transmitted
during delivery whereas reports on transplacental transmission
and fetal infection are extremely rare (Koi et al., 2002), despite a
relatively high prevalence of up to 9% of HSV-2 DNA in placental
tissue samples (Finger-Jardim et al., 2014). Likewise, as part of
the innate immune system, the placenta plays an important role
in prevention of bacterial infection during pregnancy (Mor and
Kwon, 2015). Trophoblast cells carry toll-like receptors and thus
are able to recognize bacteria via pattern recognition receptors
to elicit an immune response (Abrahams et al., 2004). Failure to
prevent bacterial infection during pregnancy may result in the
termination of pregnancy and preterm delivery. While bacterial
infections have clearly been implicated as one of the most
important reason for preterm deliveries, the specific bacterial
species that are responsible remain elusive. Nevertheless, this
situation underlines the importance of an intact placental
barrier. The potent barrier function that prevents dia-placental
transmission of pathogens is likely due to a lack of intercellular
junctions of the syncytiotrophoblast comprising most of the
maternofetal interface and an environment rich in innate
immune defense molecules (Robbins and Bakardjiev, 2012).
One part of the innate immune response consists of
antimicrobial peptides (AMPs) that are constantly expressed
or released upon TLR stimulation (Hertz et al., 2003). We
have previously shown that peptide libraries generated from
human body fluids are an excellent source for the discovery
of novel AMPs with antibacterial and antiviral activity (Münch
et al., 2014; Bosso et al., 2018). Such peptide libraries are
generated from pooled body fluids by chromatographic means
and typically consist of 100–400 peptide fractions that contain
all peptides and small proteins of the respective source material
in a lyophilized and concentrated form. Screening these libraries
for antibacterial fractions and subsequent purification of the
bioactive peptides allowed to identify, e.g., the first human β-
defensin hBD-1 (Bensch et al., 1995), antibacterial peptides
LEAP-1 and 2 (Krause et al., 2000; Krause et al., 2003), or
Casein k(63–117) (Liepke et al., 2001). Using cell-based viral
infection assays, we also discovered endogenous modulators of
HIV-1 infection, such as a novel chemokine ligand of CCR5
that blocks HIV infection (Detheux et al., 2000; Münch et al.,
2002), and a fragment of antitrypsin that inhibits HIV entry and
has been successfully tested in a phase I/II clinical trial (Münch
et al., 2007b; Forssmann et al., 2010). More recently, it led to
the discovery of an endogenous CXCR4 antagonist that blocks
CXCR4-tropic HIV infection (Zirafi et al., 2015). Moreover,
screening a semen derived peptide library identified amyloid-
forming peptides as enhancers of HIV-1 infection (Münch et al.,
2007a; Arnold et al., 2012; Röcker et al., 2018) and antibacterial
agents (Easterhoff et al., 2013). Thus, the concept of isolating
novel AMPs from body fluids resulted in the identification of
peptides that inhibited bacterial and viral infections by novel
and unexpected mechanisms. Here, we sought to adapt this
technology and generated a peptide library from human placenta
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to identify endogenous inhibitors that may restrict HSV-2
infection and bacterial pathogens.
MATERIALS AND METHODS
Generation of Peptide Library From
Placenta
Ten kilograms of human placenta were obtained from healthy
individuals in a maternity ward of a local hospital and processed
immediately after delivery. This study was approved by the
Ethics Committee of Ulm University (file number 90/17). All
subjects gave written informed consent in accordance with the
Declaration of Helsinki. First, the organs were homogenized
and peptides and small proteins extracted by an ice-cold acetic
acid extraction procedure. Thereafter, the obtained peptides
and proteins were separated by an ultrafiltration step (cut-
off: 50 kDa). The resulting peptides were then separated in a
first dimension by means of their isoelectric point using cation
exchange chromatography resulting in pH pool fractions 1–6.
Each pH pool was then further separated in a second dimension
by peptide hydrophobicity using reversed phase chromatography
resulting in a total of 250 fractions as described in detail before
(Liepke et al., 2001, 2003).
Screening the Placenta Library for
Inhibitors of HSV-2 Infection
ELVISTM cells are genetically engineered baby hamster kidney
cells that encode a lacZ gene, which is expressed upon infection
via the viral transactivator ICP10 (Enzyme-Linked Virus-
Inducible System – ELVISTM) (Proffitt and Schindler, 1995).
5,000 ELVIS cells were seeded into 96-well plates and mixed
with 10 µl of the reconstituted fractions of the placenta library.
After 10 min, cells were infected with a clinical HSV-2 isolate
(Krüger et al., 2019) and infection was determined 2 days later
by detecting the β-galactosidase activity in cellular lysates using
the Gal-Screen β-Galactosidase Reporter Gene Assay System for
Mammalian Cells (Thermo Fisher Scientific) and the Orion II
microplate luminometer (Berthold, Bad Wildbad, Germany). All
values represent reporter gene activities derived from triplicates
minus background activities derived from uninfected cells.
Triplicates are expressed as mean ± standard error derived from
two independent experiments. All experiments with infectious
viruses were performed in a BSL3∗∗ laboratory in accordance
with biosafety guidelines by Ulm University Hospital.
Mass Spectrometry
MALDI TOF MS (Matrix-assisted laser desorption/ionization
time of flight mass spectrometry) was carried out using a
LaserTec RBT II (PerSeptive Biosystems, Framingham, MA,
United States) as described in detail earlier (Ständker et al., 2010).
The instrument is equipped with a 1.2 m flight tube and a 337 nm
nitrogen laser. Positive ions are accelerated at 30 kV and laser
shots are automatically accumulated per sample. Alpha-Cyano-
4-hydroxy-cinnamic acid (CHC, Sigma–Aldrich, Deisenhofen,
Germany) was used as matrix. Accuracy of mass measurement
was 0.5%. Electrospray MS was carried out on an LCQ ion trap
mass spectrometer (Finnigan/Thermo Fisher Scientific, Bonn,
Germany) with an electrospray interface (ESI–MS) as described
previously (John et al., 2005).
Peptide Synthesis
Native HBB(112–147) was isolated in large amounts from
human placenta. Synthetic HBB(112–147) was produced using
conventional solid phase Fmoc chemistry and a Liberty blue
microwave peptide synthesizer (CEM corporation, Matthews,
NC, United States). The synthetic peptide showed identical
chromatographic and mass spectrometric properties compared to
the native peptide (purity> 95%).
Effect of HBB(112–147) on HSV-1 and
HSV-2 Infection
5,000 ELVIS cells were seeded the day before into 96-well
plates. Cells were incubated with 0–1000 µg/ml of HBB(112–
147) for 30 min at 37◦C in triplicates prior infection with
clinical isolates of HSV-1 or HSV-2. Infection rates were
determined 1 or 2 day(s) later as described above. For mechanistic
experiments or comparative analyses (Figures 1D, 2B) the HSV-2
strain 333 was used.
Effect of HBB(112–147) on Zika Virus
Infection
Virus stocks of ZIKV MR766, a ZIKV strain isolated from
a sentinel rhesus macaque in 1947 (Dick et al., 1952) were
generated by infecting Vero E6 cells. After 3–5 days the virus
was collected by centrifuging the cell supernatant for 3 min at
330 g to remove cell debris. Virus stocks were stored at −80◦C.
Vero E6 cells were cultured in DMEM supplemented with 2.5%
(v/v) heat-inactivated FCS, 2 mM L-glutamine, 1 mM sodium
pyruvate, 1x non-essential amino acid, 100 units/ml penicillin
and 100 µg/ml streptomycin. 6,000 Vero E6 cells were seeded
into 96-well plates the day before. Cells were incubated with 0–
1000 µg/ml or 0–200 µg/ml PSVBS (Schandock et al., 2017) in
triplicates for 2 h at 37◦C prior infection with ZIKV MR766.
Two days later infection rates were determined with a cell-
based ZIKV immunodetection assay. Cells were washed with
PBS and fixed with 4% paraformaldehyde (PFA) for 20 min at
room temperature. Cell permeabilization was performed with
cold methanol for 5 min at 4◦C and cells were then washed
with PBS. Afterward, cells were incubated with mouse anti-
flavivirus antibodies 4G2 in antibody buffer for 1 h at 37◦C,
washed 3 times with washing buffer and incubated with a
HRP-coupled anti-mouse antibody (1:20,000) for 1 h at 37◦C.
After 4 washing steps with PBS TMB substrate was added.
After an incubation of 5 min at room temperature, reaction
was stopped with 0.5 M sulfuric acid and absorption was
measured at 450 nm and baseline corrected at 650 nm using
an ELISA microplate reader. Values were corrected for the
background signal derived from uninfected cells and triplicates
were expressed as mean ± standard error derived from two
independent experiments.
Frontiers in Microbiology | www.frontiersin.org 3 April 2020 | Volume 11 | Article 508
fmicb-11-00508 April 6, 2020 Time: 13:31 # 4
Groß et al. A Hemoglobin Fragment With Antimicrobial Activity
FIGURE 1 | Identification of a C-terminal fragment of hemoglobin as HSV-2 inhibitor in a placenta-derived peptide library. (A) Fractions 1–39 of pH pool 4 of the
placenta library were added to ELVIS cells and subsequently infected with HSV-2. Infection rates were determined 2 days later by quantifying β-galactosidase
activities in cellular lysates. (B) MALDI-MS (left) and ESI-MS (right) spectra of fraction 19. The peaks correspond to HBB(112–147). (C) HBB(112–147) purified from
placenta and chemically synthesized peptide inhibit HSV-2 infection. Peptides were added at indicated concentrations to ELVIS cells, and cells were infected with a
clinical HSV-2 isolate. Infection rates were determined 2 days later by quantifying β-galactosidase activities in cellular lysates. (D) Activity of HBB(112–147) against a
lab strain of HSV-2 (333) and a clinical, highly ACV-resistant isolate. Peptides were added to ELVIS cells at indicated concentrations and cells were infected after
30 min incubation. Infection rates were determined 24 hpi by quantifying β-galactosidase activity.
FIGURE 2 | The hemoglobin fragment blocks an early step in the HSV-2 life cycle. (A) Indicated concentrations of HBB(112–147) were added to cells and incubated
for 30 min. Thereafter, cells were either infected directly with HSV-2 (cell treatment) or washed, supplemented with fresh medium and then infected (wash).
Additionally, virus was first exposed to HBB(112–147) for 3 h at indicated concentrations, and then these mixtures were used to infect cells (resulting in a 20-fold
dilution of the inoculum). Infection rates were determined 2 days later by quantifying β-galactosidase activities in cellular lysates. Shown are average values derived
from two experiments each performed in quadruplicates +SD. (B) In order to determine which stage of infection HBB(112–147) interferes with, peptide at indicated
concentrations was either added to cells directly prior to infection, pre-incubated for 30 min on cells at 37◦C, added 2 h post-infection (with removal of virus and
addition of fresh medium), or added after overnight infection (16 hpi). Infection was evaluated by quantifying β-galactosidase activities in cellular lysates 24 hpi.
Shown are average values derived from one experiment in triplicates +SD.
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Effect of HBB(112–147) on HIV-1 Infection
Virus stocks of CCR5-tropic HIV-1 NL4-3 92TH014.12 (Papkalla
et al., 2002) were generated by transient transfection of HEK293T
cells as described (Münch et al., 2007a). Transfection mixture was
replaced by 2 ml DMEM supplemented with 2 mM L-glutamine,
100 units/ml penicillin, and 100 µg/ml streptomycin and 2.5%
heat-inactivated FCS after overnight incubation. 40 h later, virus
was collected by centrifuging the cell supernatant to remove cell
debris for 3 min at 330 g. Virus stocks were stored at −80◦C. For
the infection assays, the reporter cell line TZM-bl was used and
cultured in DMEM supplemented with 2 mM L-glutamine, 100
units/ml penicillin, and 100 µg/ml streptomycin and 10% heat-
inactivated FCS. 10,000 TZM-bl cells were seeded the day before
into 96-well plates. The cells were incubated with 0–1000 µg/ml
of HBB(112–147) or 0–50 µg/ml of heparin as control for 2 h
at 37◦C in triplicates prior infection with HIV-1. The TZM-
bl cell line is stably transfected with an LTR-lacZ cassette and
upon infection with HIV-1 the viral protein Tat is expressed,
which activates the LTR and results in the β-galactosidase
expression. Infection rates were determined 3 days later by
detecting the β-galactosidase activity in cellular lysates using
the Gal-Screen β-Galactosidase Reporter Gene Assay System for
Mammalian Cells (Thermo Fisher Scientific) and the Orion II
microplate luminometer (Berthold, Bad Wildbad, Germany). All
values represent reporter gene activity (RLU/s) derived from
triplicates minus background activities derived from uninfected
cells. Triplicates are expressed as mean ± standard error derived
from two independent experiments.
Effect of HBB(112–147) on Rubella Virus
Infection
40–60 plaque forming units each of the three rubella virus
isolates Berlin.DE/17.97 (derived from a CRS case, genotype
1E), Bucuresti.ROU/25.03 (1G) and Rzeszow.POL/03.07 (1E)
were incubated with 0–1000 µg/ml HBB(112–147) for 1 h.
Mixtures were used to inoculate Vero cells. Cells were
treated with CMC-Overlay and incubated at 37◦C. Five
days later, Rubella virus infection was quantified by an
indirect immunocolorimetric assay using the monoclonal
"Anti-Rubella-E1(MAB 925)" antibody as described elsewhere
(Finsterbusch et al., 2009).
Colorimetric MTT- Based Cell Viability
Assay
12,000 Vero E6 cells per well were seeded in 96-well flat
bottom plates in 100 µl DMEM (supplemented with 2.5% heat-
inactivated fetal calf serum, 2 mM L-glutamine, 100 units/ml
penicillin, 100 µg/ml streptomycin, 1 mM sodium pyruvate,
and 1x non-essential amino acids) medium and incubated
overnight. The next day, the medium was removed and 90 µl
of X-vivo medium (supplemented with 2 mM L-glutamine and
100 units/ml penicillin, 100 µg/ml streptomycin) was added.
HBB(112–147) was serially 1:2 diluted and 10 µl of each dilution
was added to the cells. Cells were cultured in CO2 incubator at
37◦C and cell viability was quantified after 48 h with the MTT-
based assay. The medium was removed and 90 µl PBS and 10
µl MTT (5 mg/ml) solution were added per well. Following a
2.5 h incubation time at 37◦C, supernatant was discarded and
formazan crystals were dissolved in 100 µl 1:1 DMSO-EtOH
solution. Absorption was measured at 450 nm and baseline was
corrected at 650 nm using a Vmax kinetic microplate reader.
Protease Digestion Experiments
Proteases used were Chymase (Sigma C8118), Cathepsin
D (Sigma SRP6415), Cathepsin G (RP-77525), Cathepsin E
(Biovision 7842), Pepsin (Roche 10108057001), Trypsin porcine
pancreas (Sigma T0303-1G), Lysozyme from chicken egg
white (Sigma L6876), Napsin A (RND 8489-NA). Digestion
experiments were carried out with purified human hemoglobin
(Sigma H7379) and recombinant or purified proteases. 100 µg
hemoglobin (ca. 1.56 nmol) were digested with Chymase (in Tris-
HCl 0.05 M, pH 8.0/0.26 M NaCl), Cathepsin D, G and E (in 0.2 M
citrate buffer, pH 5.0), Pepsin (in 20 mM sodium acetate buffer,
pH 3.5), Trypsin (in 0.1 M Tris–HCl, with 10 mM CaCl2, pH
8), Lysozyme (in 10 mM Tris-HCl, pH 8) or Napsin A (in 0.2 M
NaCl, 0.1 M sodium acetate, pH 3.6). All proteases were used at
a 1:100 molar ratio (15 pmol) and reactions were incubated at
37◦C for 2 h.
SDS-PAGE
For SDS-PAGE, samples were incubated with Protein Loading
Buffer (LiCor) and reducing agent and heated. Four microgram of
hemoglobin was loaded per lane on a NuPAGETM 4–12% Bis-Tris
Protein Gel (Thermo Fisher). After running, the gel was washed
1 × 5 min with ultrapure water, then fixed with 50% MeOH/7%
acetic acid for 15 min and washed 3 × 5 min with ultrapure
water. Staining was then performed with GelCode Blue (coll oidal
coomassie) overnight. Destaining was done with ultrapure water
until the background appeared clear, the gel then imaged in a
LiCor Odyssey system.
Circular Dichroism (CD)
CD spectra of pre-incubated peptide samples were measured on
a JASCO J-1500 spectrometer in a 1 mm High Precision Cell
by Hellma Analytics. An aqueous solution (MilliQ water) of
HBB(112–147) was adjusted to pH 7 or pH 5 using 1 N HCl
solution with a final concentration of 0.1 mg/ml. The samples
with a volume of 300 µL were measured at room temperature.
The CD signal was recorded from 260 to 180 nm with a
bandwidth of 1 nm. The data pitch was set to 0.2 nm, while
the scanning speed was 5 nm/min. Each sample was measured
in three individual scans and the data were accumulated.
Spectra are baseline corrected against MilliQ water, smoothened
(Means Movement, convolution width 17) and normalized. The
data was processed in the software Spectra Analysis and CD
Multivariate SSE by JASCO.
Measurement of Napsin in Placenta
Tissue by Dot Blot
Using a methanol activated Immobilon-FL PVDF membrane
(Merck, Part# IPFL00010, LOT# R6KA6693E) detection was
carried out with anti-hNapsin A (R&D Systems Affinity Purified
Rabbit IgG, Part# AF8489, LOT# CJEB0115011) and beta-Actin
(8H10D10) Mouse antibody (Cell Signaling Technology, LOT#
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17) both 1:1000 diluted in blocking buffer over night after
blocking with LiCor Odyssey Blocking Buffer (TBS) (Part# 927-
50000, LOT# X2321). Detection was performed with IRDye
800 CW Goat anti-Rabbit 926-32211 (LOT# C70426-05) and
IRDye 680RD Goat anti-Mouse 926-68070 (LOT# C70427-05)
antibodies 1:10000 diluted for 1 h on a Li-Cor Odyssey CLx
system with Image Studio (ver 5.2).
Identification of HBB(112–147) in the HB
Digested Sample by LC-ESI-MSMS
Hemoglobin digests were reduced with 5 mM DTT for 20 min
at RT and subsequently alkylated with iodoacetamide for 20 min
at 37◦C. The samples were measured using an LTQ Orbitrap
Velos Pro system (Thermo Fisher Scientific) online coupled to an
U3000 RSLCnano (Thermo Fisher Scientific) uPLC as described
previously (Mohr et al., 2015), with the following modifications:
For separation, a binary gradient consisting of solvent A (0.1%
FA) and solvent B (86% ACN, 0.1% FA) was employed. After
loading onto the precolumn, the sample was concentrated and
washed in 5% B for 5 min. In a first elution step, the percentage
of B was raised from 5 to 15% in 5 min, followed by an increase
from 15 to 40% B in 30 min. The column was washed with 95%
B for 4 min and re-equilibrated for subsequent analysis with
5% B for 19 min. For visualization, spectral data was exported
from the datafile using XCalibur Qual Browser 2.2 (Thermo
Fisher Scientific, Bremen, Germany). Database searches were
performed using PEAKs X1 (Zhang et al., 2012). For peptide
identification, MS/MS spectra were correlated with the UniProt
human reference proteome set2. Carbamidomethylated cysteine
was considered as a fixed modification along with oxidation (M)
as a variable modification. False discovery rates were set on the
peptide level to 1%.
Bacterial Strains
Strain Origin
P. aeruginosa BSU856 ATCC27853
P. aeruginosa BSU1294 Clinical isolate, Ulm collection
P. aeruginosa BSU1295 Clinical isolate, Ulm collection
P. aeruginosa BSU1455 Clinical isolate, Ulm collection
P. aeruginosa BSU1456 Clinical isolate, Ulm collection
P. aeruginosa BSU1457 Clinical isolate, Ulm collection
P. aeruginosa BSU1458 Clinical isolate, Ulm collection
Carbapenem resistant
(Hagemann et al., 2018)
Radial Diffusion Assay
Bacteria were cultured at 37◦C in a 5% CO2 atmosphere
overnight, pelleted by centrifugation and washed in 10 mM
sodium phosphate buffer. Following resuspension in 10 mM
sodium phosphate buffer optical density was determined at
600 nm (OD600 nm). 2 × 107 bacteria were seeded into a petri
1http://www.bioinfor.com/peaks-studio
2www.uniprot.org
dish in 1% agarose dissolved in 10 mM sodium phosphate buffer.
After cooling at 4◦C for 30 min 2–3 mm holes were punched into
the 1% agarose. Peptides adjusted to the desired concentration
in 10 µl of ddH2O were filled into the agar-holes. Following
incubation at 37◦C in ambient air for 3 h plates were overlaid
with 1% agarose solution containing 3% tryptic soy broth (TSB)
dissolved in 10 mM phosphate buffer. Inhibition zones in cm
were determined following 16–18 h incubation time at 37◦C in
a 5% CO2 atmosphere and used to evaluate antibacterial potency.
For LPS inhibition experiments, 62.5 µg/ml HBB(112–147) was
incubated for 1 h at 37◦C together with varying concentrations
of LPS of P. aeruginosa 10 (Sigma L9143) followed by the same
procedure as described above.
Survival Assay
P. aeruginosa BSU856 cells were grown in THY broth [Todd-
Hewitt Broth (Oxoid) supplemented with 0.5% yeast extract
(BD, Miami, United States)] at 37◦C in a 5% CO2 atmosphere
overnight. 1 ml of the culture adjusted to an OD600nm of
0.1 was centrifuged and the bacterial pellet was resuspended
in 1 ml of assay medium (5% TSB dissolved in 0.9% NaCl
adjusted to different pH values). 90 µl microliter of the bacterial
suspension was mixed with 10 µl of HBB(112–147) of the desired
concentration or with 10µl of ddH2O (negative control) followed
by incubation at 37◦C. Samples were taken at the indicated
time points, dilutions were prepared and platted on sheep blood
agar plates (TSA + SB, Oxoid, Basingstoke, United Kingdom).
Colony Forming Units (CFU) were counted after overnight
incubation of the agar plates at 37◦C in a 5% atmosphere and
the survival of the cells was calculated in comparison to the
CFU present at the beginning of the experiment (t = 0 min) and




An equivalent of 100 µl of an OD600 nm of 0.1 of mid-exponential
P. aeruginosa BSU856 cells were harvested by centrifugation and
resuspended in 5% TSB dissolved in 0.9% NaCl adjusted to three
different pH values (pH 7, pH 5.5, pH 4.5). The samples were
treated with HBB(112–147) of different concentrations or were
mock treated with ddH2O. After incubation at 37◦C for 1 h,
the cells were pelleted and resuspended in 5% TSB dissolved in
0.9% NaCl adjusted to pH 7 containing 0.2 µM SYTOX green
stain. The fluorescent intensity of the samples was measured in
a Tecan infinite M200 plate reader with an excitation wavelength
of 488 nm and an emission wavelength of 530 nm. The relative
fluorescence of the samples was calculated by normalizing the
peptide treated samples to the mock treated samples grown in the
corresponding assay medium.
Transmission Electron Microscopy
P. aeruginosa BSU856 cells, grown till mid-exponential growth
phase, were harvested by centrifugation and resuspended in 5%
TSB dissolved in 0.9% NaCl (pH 4.5). 5 × 10 (Mor and Kwon,
2015) cells were treated with 0.1 mM HBB(112–147) for 1 h at
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37◦C followed by centrifugation. The pelleted cells were fixed
with 2.5% glutaraldehyde containing 1% saccharose in phosphate
buffer (pH 7.3). Samples were washed five times with phosphate
buffer and post-fixed in 2% aqueous osmium tetroxide. After
dehydrating the samples in a graded series of 1-propanol, they
were blockstained in 1% uranyl acetate and embedded in Epon.
Ultra-thin sections (80 nm) were collected on copper grids,
contrasted with 0.3% lead citrate for 1 min and imaged in a Zeiss
TEM 109 or in a Jeol TEM 1400.
Evolutionary Conversation of
HBB(112–147) Sequence in Hemoglobin
The following orthologs of the hemoglobin beta globin chain
were included in the sequence analysis (numbers give accession
numbers): Homo sapiens (Human) P68871; Rattus norvegicus
(Rat) P02091; Mus musculus (Mouse) P02088; Sus scrofa
(Pig) P02067; Oryctolagus cuniculus (Rabbit) P02057; Pan
troglodytes (Chimpanzee) P68873; Bos taurus (Bovine) P02070;
Mesocricetus auratus (Golden hamster) P02094; Ovis aries
(Sheep) P02075; Macaca fascicularis (Cynomolgus monkey)
P68223; Panthera pardus orientalis (Amur leopard) P04244;
Capra hircus (Goat) P02077; Bradypus tridactylus (Pale-throated
three-toed sloth) P14526; Ailuropoda melanoleuca (Giant
panda) P18983; Dasypus novemcinctus (Nine-banded armadillo)
P02087; Macropus eugenii (Tammar wallaby) Q6H1U7;
Tachyglossus aculeatus aculeatus (Australian echidna) P02110;
Xenopus laevis (African clawed frog) P02132; Chelonoidis
carbonarius (Red-footed tortoise) Q98905; Meleagris gallopavo
(Common turkey) P81023; Gallus gallus (Chicken) P02112;
Danio rerio (Zebrafish) Q90486;
Protein sequences were aligned using Clustal W3 and residue
conservation was determined using the Scorecons Server4.
Shannon’s information theoretical entropy was applied to
measure the diversity of amino acids at a specific site. Residues
were classified into one of seven types: aliphatic (AVLIMC),
aromatic (FWYH), polar (STNQ), positive (KR), negative (DE),
special conformations (GP) and gaps. This convention follows
that of Mirny and Shakhnovich (1999). Statistical calculations
were performed with a two-tailed unpaired Student’s t-test using
Graph Pad Prism Version 5.0.
RESULTS
Identification of Placenta-Derived
Peptide Fractions That Simultaneously
Reduce HSV-2 Infection and Growth of
P. aeruginosa
In an attempt to identify endogenous antiviral and antibacterial
peptides in placenta, we generated a peptide library from 10 kg
of pooled homogenized placental tissue. Human tissue was




local hospital and was processed immediately after delivery.
Peptides were extracted by an ice-cold acetic acid extraction
procedure and the obtained peptide and protein fractions were
separated by ultrafiltration (cut-off: 50 kDa). The peptide fraction
was then chromatographically separated and resulted in approx.
250 different peptide containing fractions that were used for
bioscreening (Liepke et al., 2003). To identify peptides with anti-
HSV-2 activity, all fractions of pH pools 0–4 were dissolved
in PBS and added to ELVISTM cells, an HSV-2 reporter cell
line expressing β-galactosidase upon viral infection. Thereafter,
cells were infected with HSV-2 and infection rates determined
2 days later (before occurrence of viral CPE) by quantifying β-
galactosidase activity in cellular lysates. Only fraction 8 of pH
pool 2 and fractions 18–20 of pH pool 4 markedly suppressed
HSV-2 infection (Supplementary Figure S1A). To confirm
these results, a twice as high concentration of these fractions
was tested again for anti-HSV-2 activity. Antiviral activity of
fraction 8 of pH pool 2 could not be confirmed (not shown),
however, fractions 18 and 19 inhibited HSV-2 infection by∼80%
(Figure 1A). Interestingly, the same fractions of pH pool 4
were also the most potent inhibitors of growth of P. aeruginosa
(Supplementary Figure S1B).
Subsequent mass spectrometric analysis by MALDI-MS
revealed a predominant peptide with a mass of 3902.5 Da
(Figure 1B). Edman sequencing allowed to determine the
N-terminal sequence starting with VCVLA. . . and database
search identified the corresponding peptide: a 36-mer derived
from the C-terminal region of the hemoglobin subunit β
(HBB) encompassing residues 112–147 (Figure 1B, numbering
according to UniProt sequence P68871). The same peptide
was previously isolated by us from a similar placenta library
and shown to exert antibacterial activity against Gram-positive
and -negative bacterial species (Liepke et al., 2003). However,
no antiviral activity was reported. Thus, we next determined
the anti-HSV-2 activity of placenta-purified HBB(112–147)
and that of the chemically synthesized version. As shown
in Figure 1C, both peptides resulted in a dose-dependent
inhibition of HSV-2 infection with IC50 values in the median
µg/ml range, without causing cytotoxic effects (Supplementary
Figure S2). Thus, placenta contains a C-terminal hemoglobin
β fragment that restricts growths of bacteria and inhibits HSV-
2 infection. As resistance to conventional anti-HSV drugs such
acyclovir (ACV) is a growing problem especially with HSV-
2 in immunocompromised patients (Piret and Boivin, 2011),
we investigated whether HBB(112–147) is also effective against
ACV-resistant HSV-2. Indeed, a highly ACV-resistant clinical
HSV-2 isolate was equally inhibited by the peptide as the HSV-2
333 lab strain (Figure 1D).
HBB(112–147) Inhibits HSV-2 Infection by
Blocking Viral Entry
We next analyzed the antiviral mechanism of HBB(112–147).
For this, cells were exposed to increasing concentrations of the
peptide for 30 min. Thereafter, cells were either infected directly
with HSV-2 (cell treatment), or washed and subsequently infected
(wash). Additionally, virions were first treated with the peptide
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for 3 h at indicated concentrations, and then used to infect
cells, resulting in 20-fold reduced concentrations of HBB(112–
147) in cell culture (virion treatment). No inhibitory activity was
observed if peptide was removed by washing prior to infection,
suggesting that the hemoglobin fragment needs to be present
during infection and that it does not induce an antiviral state of
cell (Figure 2). If added 30 min prior to infection, HBB(112–147)
dose-dependently reduced infection with an IC50 of∼200 µg/ml,
confirming results shown above (Figure 2) and demonstrating
that it blocks an early step in the viral life cycle. Interestingly,
exposure of the virions prior to infection also suppressed
infection (virion treatment). The two highest concentrations
tested, 500 and 1000 µg/ml, reduced HSV-2 infection by 60 and
78%, respectively. These concentrations correspond to final cell
culture concentrations of 25 and 50 µg/ml, that hardly reduce
infection, suggesting that HBB(112–147) seems to interact with
the HSV-2 particles in a way that prevents infection. Consistent
with an entry-inhibiting effect, HBB(112–147) only exerted
potent inhibition if added to cells prior to infection (directly or
with 30 min pre-incubation), but did not inhibit HSV-2 infection
if added 2 or 16 h after infection (Figure 2B). This is consistent
with inhibition by Heparin, a well-described HSV entry inhibitor
preventing virion adsorption (Supplementary Figure S3).
HBB(112–147) Does Not Affect HSV-1,
HIV-1, Zika and Rubella Virus Infection
We next tested whether the hemoglobin fragment may also
inhibit HSV-1 infection. Surprisingly, HBB(112–147) did not
block infection of a clinical HSV-1 isolate whereas it was active
against a second HSV-2 isolate tested (Figure 3A). We next
determined the effect of the peptide on viruses for which dia-
placental transmissions have been reported. HBB(112–147) and
the polyanion heparin as control (Shieh et al., 1992) were titrated
on TZM-bl cells, an HIV-1 reporter cell line that expresses
β-galactosidase upon infection. As shown in Figure 3B, the
polyanion inhibited HIV-1 infection in a dose-dependent manner
whereas HBB(112–147) was inactive. Likewise, no inhibition
of Zika Virus (ZIKV) infection of Vero cells was observed, as
shown by immunodetection assay using a flavivirus antibody-
based ELISA (Müller et al., 2018), whereas the macromolecular
polyanion PSVBS (Schandock et al., 2017) was active (Figure 3C).
For both ZIKV and HIV-1, even virus treatment with up to
1 mg/ml HBB(112–147) on virus did not result in any inhibition,
while the molecular tweezer CLR01 resulted in destruction of
both virions as previously published (Supplementary Figure
S4). Similarly, no antiviral effect of HBB(112–147) against three
different Rubella virus (RUBV) isolates, one isolated from a
patient with congenital rubella syndrome, were observed, as
shown by indirect immunocolorimetric detection of RUBV
infection in Vero cells (Figure 3D). Thus, HBB(112–147)
is no broad-spectrum antiviral agent but rather a specific
inhibitor of HSV-2.
Proteolytic Generation of HBB(112–147)
In adults, the most common hemoglobin type is a tetramer called
hemoglobin A, consisting of two α and two β subunits that
are non-covalently bound (α2β2). In this tetrameric state, the
putative protease cleavage site in the β subunits at positions L111
and V112 is not solvent exposed and hence not accessible for
proteases (Supplementary Figure S5). However, α2β2 rapidly
dissociates into respective dimers and monomers at acidic pH
(Huang et al., 2013). Thus, we analyzed whether HBB(112–
147) can be generated under low pH conditions by acidic
proteases. In order to determine which proteases might be
responsible for the proteolytic liberation of HBB(112–147)
from full-length hemoglobin, purified human hemoglobin was
subjected to digestion by a panel of 8 proteases. Digestion with
Chymase, Cathepsin D as well as Pepsin, Trypsin and Napsin
A (Figure 4) resulted in lower signal for uncleaved monomeric
globin (16 kDa) and generation of smaller fragments. As
bands consistent with a size of HBB(112–147) at approximately
4 kDa were especially observed for digestions with Cathepsin
D, Pepsin and Napsin A, those digestions were also subjected
to mass spectrometric analysis in order to confirm generation
of HBB(112–147). Indeed, Cathepsin D and Napsin A-digested
hemoglobin yielded a signal consistent with generation of
HBB(112–147) (Supplementary Figure S6). No such signal was
detected in Pepsin-digested hemoglobin (not shown), suggesting
generation of another peptide fragment with similar size. In
kinetic digestion experiments with Cathepsin D, a fragment
running at the same height as synthetic HBB(122–147, 3902.5
kD) was observed already at the first time point (20 min),
while no fragments were generated in a buffer-only mock
digestion (Supplementary Figure S7). As Napsin A has not
been previously described to be expressed in placental tissue,
we analyzed a placenta homogenate by dot blot analyses using a
Napsin A specific antibody. As shown in Supplementary Figure
S6, Napsin A is readily detectable in the placenta homogenate
(Supplementary Figure S8).
Conservation Score and Biophysical
Characterization of HBB(112–147)
To determine the evolutionary conservation of the HBB(112–
147) peptide sequence, we aligned the β-hemoglobin orthologs
of 22 vertebrate species (Supplementary Figure S9, bottom
right) and determined the conservation score, i.e., the diversity
of amino acids at each site (Supplementary Figure S9, top).
The average conservation score of residues within HBB(112–
147) was not significantly different from that outside this
region (Supplementary Figure S9, bottom left). This suggests
that the HBB(112–147) sequence is evolutionarily not more
conserved than the remainder of the β-hemoglobin protein.
Analysis of the HBB(112–147) sequence by ProtParam tool
revealed a positive isoelectric point (pI) of 9.05, a net excess
of two positively charged residues, and an estimated half-life of
>100 h in mammalian reticulocytes, characterizing the peptide
as very stable. We determined the CD spectra of HBB(112–
147) at neutral and acidic pH. As shown in Figure 5, the
peptide adopts mainly a random coil structure with modest
contribution of other structures while the content of secondary
structures is not changed significantly if the peptide is dissolved
in solutions with acidic or neutral pH. This lack of ordered
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FIGURE 3 | Antiviral activity of HBB(112–147) against HSV-1, HIV-1, ZIKV and RUBV. (A) Peptide was added to ELVIS cells and cells then infected with one clinical
HSV-1 isolates and a second isolate of HSV-2. Infection rates were determined two days later by quantifying β-galactosidase activities. (B) TZM-bl reporter cells
were incubated with HBB(112–147) or the polyanion Heparin and then infected with HIV-1. Three days post-infection, infection was determined by measuring
β-galactosidase activities in cellular lysates. (C) Vero E6 cells were supplement with HBB(112–147) or the macromolecular compound PSVBS and infected with
ZIKV-MR766. Two days later, infection was quantified by an in cell ELISA that detected the viral E protein. Values shown in (A–C) are mean values derived from
triplicate experiments. (D) Three rubella virus isolates were exposed to indicated concentrations of HBB(112–147) and then inoculated onto Vero cells. Cells were
treated with CMC-Overlay and incubated at 37◦C. Five days later, RUBV infection was quantified by an indirect immunocolorimetric assay using the monoclonal
anti-Rubella-E1(MAB 925) and photos taken by a digital camera.
structures and high random coil content could be an indication
of intrinsically disordered structures (Chouard, 2011; Wright
and Dyson, 2015). Several antimicrobial peptides (AMPs) are
known to form disordered regions that could adopt more
ordered states upon binding to their cellular targets (Dyson and
Wright, 2005; Sugase et al., 2007; Chouard, 2011; Wright and
Dyson, 2015). However, the functional role of these intrinsically
disordered proteins has been recognized only recently (Dyson
and Wright, 2005), and further analysis and structure mining
would be necessary to clarify whether the high random
coil content of HBB(112–147) could change upon interaction
with its target.
HBB(112–147) Inhibits Growth of Several
Clinical Isolates of Pseudomonas
aeruginosa
P. aeruginosa is a frequent nosocomial pathogen causing many
life-threatening infections that are often complicated through
the worldwide occurrence of multi-resistant strains. To assess
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FIGURE 4 | Generation of HBB(112–147) by proteolytic digestion. Purified human hemoglobin was incubated with several proteases (at 1:100 molar ratio) and
digested for 2 h at 37◦C or incubated with the respective buffer only for the same time (bottom). The reactions were then separated by SDS-PAGE and total protein
stained by colloidal coomassie. For the bottom panel, human hemoglobin was incubated in the respective digestion buffers without addition of protease and
separated as well.
if placental tissue may represent a source for AMPs exhibiting
anti-pseudomonal activity we screened a peptide library against
P. aeruginosa strain ATCC27853. One of the fractions with the
highest activity against P. aeruginosa (fraction 19) contained large
amounts of HBB(112–147) (Supplementary Figure S1B). To
substantiate these results and to confirm that the antimicrobial
compound in this fraction was HBB(112–147), various clinical
P. aeruginosa isolates and strain ATCC27853 were evaluated for
susceptibility against this purified hemoglobin fragment in radial
diffusion assays. All of the strains investigated demonstrated a
susceptibility to HBB(112–147) in a dose dependent manner
down to concentrations as low as than 15.6 µg/ml (Figure 6). To
explore if HBB(112–147) is also effective against a multiresistant
strain of this species, we determined HBB(112–147) susceptibility
of a carbapenem resistant P. aeruginosa strain, that had
previously shown antibiotic susceptibility only to Colistin, a
toxic, last resort antibacterial compound (Hagemann et al.,
2018). Inhibition zones for this strain were indistinguishable
from values obtained for other clinical P. aeruginosa isolates
(Figure 6, red column).
The Antibacterial Effect of HBB(112–147)
Is pH Dependent
Many antimicrobial peptides show highest antibacterial activity
at a pH below 7 (Malik et al., 2016) and isolation of
HBB(112–147) from placental tissue was carried out under acidic
conditions. Furthermore slightly acidic conditions are present
in the radial diffusion assay that we used for screening of the
placental library as well as for the evaluation of the susceptibility
of P. aeruginosa against HBB(112–147). To investigate a potential
pH dependency of the antimicrobial effect of HBB(112–147),
bacterial survival assays were carried out under different
pH conditions. An overnight culture of P. aeruginosa was
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FIGURE 5 | CD spectra of HBB(112–147). (A) The peptide was dissolved in MilliQ water at pH 5 and 7 and CD spectra were recorded. (B) Secondary structure
elements of HBB(112–147) based on the analysis of CD spectra results; spectra were baseline corrected against MilliQ water, smoothened and normalized. Values
shown were derived from triplicate measurements (+SD).
FIGURE 6 | Antibacterial activity of HBB(112–147) against clinical Pseudomonas aeruginosa isolates. The effect of indicated concentrations of HBB(112–147) was
tested against several clinical isolates of Pseudomonas aeruginosa in a radial diffusion assay. BSU1458 (red) is a carbapenem/multi-drug resistant P. aeruginosa
isolate. Depicted are inhibition zones in cm observed in a radial diffusion assay (n = 3, mean values +SD).
resuspended to an OD of 0.1 and adjusted to pH values of 4.5,
5.5, and 7. Following exposure to 5–50 µM concentrations of
HBB(112–147) bacterial survival was quantified through CFU
measurements. After 15 min at pH 4.5 less than 10% of the
P. aeruginosa cells growing in control tubes of the same pH
without HBB(112–147) were still viable, a value which dropped
to less than 1% after 60 min (Figure 7A). At pH 7 little if
any growth inhibition could be observed when compared to the
appropriate controls even after 60 min at 50 µM concentration of
HBB(112–147) (Figure 7A).
HBB(112–147) Destroys the Membrane
Integrity of P. aeruginosa
Bacterial membrane damage is one of the most common
modes of action for AMPs. To elucidate if this is also the
relevant antimicrobial mechanisms for HBB(112–147) against
P. aeruginosa, we investigated bacterial membrane integrity via
SYTOX green uptake into bacterial cells. Intracellular SYTOX
green enrichment and staining of nucleic acids occurs only
upon disruption of bacterial membranes. Following exposure
of HBB(112–147) for 1 h at 37◦C, membrane integrity was
compromised already at 5 µM concentrations for pH 4.5
and showed a clear dose dependent effect (Figure 7B). In
support of the results obtained for the antibacterial effect, also
membrane permeabilization was pH dependent. At pH 7 even
at a 50 µM concentration of HBB(112–147) hardly any SYTOX
enrichment could be detected in P. aeruginosa. To visualize loss
of membrane integrity transmission electron microscopy (TEM)
was performed. Treatment of P. aeruginosa cells was carried
out with 0.1 mM HBB(112–147) for 1 h at pH 4.5. Subsequent
TEM pictures revealed the presence of multiple lysed bacterial
cells and leakage of intracellular content (Figures 8C,D), while
controls appeared intact (Figures 8A,B). Areas of disrupted
bacterial membranes are clearly visible in TEM (Figure 8E) of
bacterial cells exposed to HBB(112–147). To further investigate
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FIGURE 7 | Effect of HBB(112–147) on bacterial survival and membrane integrity. (A) The effect of HBB(112–147) on P. aeruginosa growth was quantified in a
survival assay. 5, 10, and 50 µM of the peptide were added to an overnight culture of P. aeruginosa at pH values of 7, 5.5, and 4.5 for 15, 30, and 60 min. Bacteria
were quantified by CFU determination. Values are expressed as % of growth controls not exposed to HBB(112–147). Data shown are average values derived from
three biological replicates +SD. (B) Plasma membrane damage of P. aeruginosa following HBB(112–147) treatment for 1 h at 37◦C, was tested at indicated pH
values by uptake of SYTOX green and subsequent quantification of fluorescence in a Tecan infinite M200 plate reader. Shown are mean values and SD of n = 3.
Values shown are relative fluorescence units (RFU).
bacterial surface molecules of P. aeruginosa, that might interact
directly with HBB(112–147), we performed a preincubation of
HBB(112–147) with P. aeruginosa LPS for 1 h. Subsequent testing
of antimicrobial activity in radial diffusion assays, showed a dose
dependent reduction of the inhibitory effect (Supplementary
Figure S10), indicating that HBB(112–147) binds to LPS.
DISCUSSION
In the present study, we screened a placental peptide library
for antiviral agents and identified a C-terminal fragment of
β-hemoglobin as specific inhibitor of HSV-2 infection. This
peptide, termed HBB(112–147) has previously been isolated from
the same source as broad-spectrum antibacterial agent (Liepke
et al., 2003). Here, we confirm and expand these findings and
demonstrate that HBB(112–147) is also active against clinical
isolates of P. aeruginosa, including a multiple-drug resistant
strain (Hagemann et al., 2018). Our novel data also show that
the peptide ruptures the bacteria cell wall in a pH-dependent
manner resulting in release of the cytosol and consequently
cell death. Moreover, we show that HBB(112–147) is generated
from tetrameric hemoglobin by ubiquitously expressed aspartic
proteases under acidic conditions, which are a hallmark of
inflammatory tissues.
HBB(112–147) is the predominant peptide in those fractions
of the peptide library (fr. 18 and 19 of pH pool 4) that inhibited
HSV-2 and P. aeruginosa. Peptide purified from placenta and the
synthetic version showed comparable antiviral activity, strongly
suggesting that only the HBB(112–147) fragment but no other
peptide or protein are responsible for the observed antiviral
activity in these fractions. Unlike its broad antibacterial activity
against various Gram-positive and -negative bacteria (Liepke
et al., 2003), HBB(112–147) selectively inhibits HSV-2 but no
other viral pathogen, suggesting a different antibacterial and
antiviral mechanism. In fact, we show that HBB(112–147) has
direct bacterial cell killing activity by inducing ruptures in the
bacterial cell wall. We also demonstrate that HBB(112–147)
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FIGURE 8 | Transmission electron microscopy images of P. aeruginosa. Bacterial cells were grown to midlogarithmic phase and exposed to buffer (A,B) or 0.1 mM
HBB(112–147) at pH 4.5 for 1 h (C,D). Cells were fixed with 2.5% glutaraldehyde and dehydrated in a graded series of 1-propanol. Following embedding in Epon,
ultra-thin sections (80 nm) were collected on copper grids, and imaged in a Zeiss TEM 109 or in a Jeol TEM 1400. Areas showing loss of membrane integrity are
indicted by black arrows (E). Scale bars are 5 µm (A,C) and 1 µm (B,D).
interacts with HSV-2 particles in a way that prevents viral entry,
whereas no inhibition of other enveloped viruses (HIV-1, ZIKV,
RUBV, and HSV-1) was observed. Virion pre-treatment of HSV-
2 did not yield overall higher inhibition rates, indicating that the
effect is not due to virion disruption. As IC50 were nonetheless
substantially lower in virion- compared to cell-treatment mode,
we propose HBB(112–147) to interfere with the interaction
of viral glycoproteins with a cellular receptor. It cannot be
excluded that non-protein structures of the viral envelope (lipids,
carbohydrates) might also be targets of HBB(112–147). However,
infection-inhibitory membrane interactions would likely result in
membrane disruption (as e.g., for CLR01 used in Supplementary
Figure S4) and are not consistent with the overall higher
inhibition observed upon cell treatment (Figure 2).
HSV-1 and HSV-2 are closely related viruses with a high
sequence homology of 83% in the protein-coding regions (Dolan
et al., 1998), which mediate cellular attachment and entry.
The differential activity of HBB(112–147) against HSV-1 and
HSV-2 may reflect differences in the glycoprotein sequence
and/or composition of both viruses. In fact, both viruses differ
in their sensitivity to polyanions (Hutton et al., 1973) and
polycations (Langeland et al., 1987, 1988), differential binding
to heparan sulfate (HS)/heparin chains (Herold et al., 1996;
Trybala et al., 2000) and stimulation of viral infection in
glycosaminoglycan-deficient cells by dextran sulfate (Dyer et al.,
1997). Collectively these data suggest that HBB(112–147) may
interact with an HSV-2 specific glycoprotein that is important
for viral attachment and/or entry. The fact that antibacterial
and antiviral action is exerted via a different mechanism is
likely due to conformational changes of HBB(112–147) upon
encounter of LPS on the surface of P. aeruginosa as it has
been described for several other AMPs (Pulido et al., 2012).
The subsequent rearrangements and membrane disruption may
thus only occur at bacterial membranes and not the surface of
virions. Whether interaction with viral surfaces leads to other
conformation changes or the peptide is active as a random coil
in this scenario remains to be studied.
As a common sexually transmitted infection, HSV-2 has
a relatively high seroprevalence of 10–30% in the US and
Europe and up to 30–80% in the female population of some
developing countries (Malkin, 2004; Weiss, 2004; Looker et al.,
2015). As oral HSV-1 infection is typically already acquired
during childhood or adolescence, it is much more prevalent at
ca. 60–90% seropositivity in developed countries (Smith and
Robinson, 2002). While infection with either virus is often either
asymptomatic or results in characteristic skin lesions, severe
outcomes such as herpes simplex encephalitis (HSE) in neonates
or aseptic meningitis in adults are also observed (Berger and
Houff, 2008). Neonatal HSE is a particularly severe disease
caused by HSV-2 infection in 70% of cases, leading to CNS
involvement in 70% of cases and death in 60% of cases if
untreated (CPSP, 2002). Interestingly, vertical transmission of
HSV-2 from mother to child happens perinatally in the majority
of cases, while only 5% of transmission occur in utero (Kimberlin,
2007). Despite relatively high shedding rates (compared to HSV-
1) in infected women (Scoular, 2002), vertical HSV transmission
is generally a rare event, occurring in up to 1/3,000 live
births (Brown et al., 2005) and HSV-2 is responsible for the
majority of those infections (Avgil and Ornoy, 2006). Multiple
factors affect these low transmission rates: the lack of HSV
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receptor expression on syncytiotrophoblasts (Koi et al., 2002),
transplacental transmission of protective antibodies (Brown et al.,
2005) as well as low viremia in most HSV-2 patients in absence of
primary infection. Despite these factors, one clinical study found
HSV-2 DNA in 9% of maternal-side placenta tissue with 39% of
these cases also testing positive for HSV-2 DNA on the fetal side;
notably despite lack of symptoms in any of the patients at delivery
(Finger-Jardim et al., 2014). Congenital infection with other
herpesviruses is substantially more common: CMV infection
occurs in 0.2–2.2/100 live births, while congenital VZV infection
is reported with an incidence of up to 0.4–9/100 births. Notably,
these numbers account for congenital infections, meaning in
utero transmission of the virus, which is a minor occurrence for
HSV-2. Considering the potent inhibition of HSV-2 infection by
HBB(112–147) and the abundance of the precursor in placental
tissue, a role of the peptide in preventing vertical transmission
of HSV-2 in utero seems plausible and further experiments are
needed to confirm its role in vivo.
P. aeruginosa is listed among the six bacterial species
summarized as ESKAPE pathogens that pose an increased health
risk to patients due to their common multidrug resistance
profiles (Pendleton et al., 2013). It is responsible for a wide
variety of nosocomial infections and the major bacterial agent
in chronic lung infections of cystic fibrosis patients (Malhotra
et al., 2019). In cystic fibrosis as well as in other serious
P. aeruginosa caused infections the steady increase of multi-
resistant P. aeruginosa strains severely limits therapeutic options.
Often highly toxic substances such as Colistin represent the only
therapeutic options for multidrug resistant strains (Hagemann
et al., 2018). To address this alarming clinical problem, we
used the same peptide library originating from human placenta
to identify antimicrobial substances targeting P. aeruginosa.
Interestingly the fractions exhibiting the highest antimicrobial
activity against P. aeruginosa were also the most active fractions
against HSV-2. While screening was carried out with an ATCC
laboratory strain, subsequent determination of antimicrobial
activity was done on P. aeruginosa clinical isolates including a
multidrug resistant carbapenemase expressing strain (Hagemann
et al., 2018). Susceptibility to HBB(112–147) showed a dose
dependent effect and proved to be very similar in all of the
clinical isolates we tested. Interestingly, many AMPs display
antimicrobial activity preferably at low pH conditions. The
survival rates of P. aeruginosa in the presence of HBB(112–
147) were greatly affected by pH and showed the highest
activity of HBB(112–147) at a pH of 4.5. Acidic pH values
are found in various host niches such as the vaginal tract, the
skin, the stomach, intracellularly in lysosomal compartments
and at sites of bacterial infections. Many of the well-known
human AMPs such as lactoferrin, LL37, dermicidin, kappacins
and histatins show pH dependent antimicrobial activities
(Malik et al., 2016).
Indeed, biophysical analysis of HBB(112–147) revealed
features characteristic for many AMPs. This class of innate
host defense molecules are 12–50 amino acids, include two or
more positively charged residues provided by arginine, lysine
or, in acidic environments, histidine, and a large proportion
(generally> 50%) of hydrophobic residues (Sitaram and Nagaraj,
2002; Papagianni, 2003; Dürr et al., 2006). HBB(112–147) is
a 36-mer with three positively charged residues (K10, K22,
K34), and additionally four histidine residues, which may
explain the increased antibacterial activity of HBB(112–147)
under acidic conditions. Conformational changes of AMPs
leading to an increase of alpha helical structures occur at
low pH and represent a hallmark of pore forming AMPs.
Under low pH conditions protonation of histidine residues
occurs in some AMPs (Kacprzyk et al., 2007) and promotes
conformational changes that improve their capacity for insertion
into bacterial membranes and pore formation (Khatami et al.,
2014). Many AMPs are unstructured in free solution [as
HBB(112–147) is], and fold into their final configuration
upon partitioning into biological membranes resulting in the
disruption of bacterial membrane integrity. Especially for pH
dependent AMPs, bacterial pore formation is the preferred
molecular mechanism (Malik et al., 2016). Based on our SYTOX
experiments that detected pH-dependent membrane damage,
bacterial lysis seems to occur in P. aeruginosa upon exposure to
HBB(112–147). This interpretation is supported by the analysis of
TEM pictures that shows defects of bacterial membranes as well
as spilling of bacterial intracellular content and a large proportion
of apparently lysed bacterial cells. To achieve bacterial lysis,
HBB(112–147) needs to interact with bacterial surface structures.
LPS has previously been implicated to interact with HBB(112–
147) (Liepke et al., 2003), however, if this interaction could be
important in regard to the antimicrobial properties of HBB(112–
147) has not been investigated. We could show here that the
preincubation of HBB(112–147) with soluble P. aeruginosa LPS
reduced its antibacterial activity in a dose dependent manner,
most likely through competitive inhibition. The cationic and
hydrophobic nature of many AMPs facilitates the interaction
with negatively charged bacterial molecules such as LPS. Several
antimicrobial peptides are known to interact with LPS, targeting
AMPs to the bacterial cell surface as well as exerting an anti-
inflammatory effects by blocking host reactions like cytokine
release (Pulido et al., 2012). Based on the data we obtained,
HBB(112–147) appears to have a similar mode of action and can
be classified as typically cationic AMP.
The prerequisites for the generation of HBB(112–147) –
the hemoglobin precursor and the peptide releasing protease
Cathepsin D – are given almost everywhere in the body. We
show that HBB(112–147) is released under acidic conditions
by Cathepsin D, an aspartic endo-protease that is ubiquitously
distributed in lysosomes of all cells (Barrett and Cathepsin,
1970). The main function of Cathepsin D is to degrade proteins
and activate precursors of bioactive proteins in pre-lysosomal
compartments (Diment et al., 1989). However, Cathepsin D can
also be found in the extracellular space (Lkhider et al., 2004;
Benes et al., 2008). The trigger for the proteolytic degradation
of hemoglobin and the liberation of HBB(112–147) is an acidic
pH which is a hallmark of inflammatory tissues and infections
(Erra Díaz et al., 2018). A low pH not only activates the protease
but also results in the dissociation of the hemoglobin subunits
and the exposure of the otherwise buried proteolytic cleavage site
(Huang et al., 2013). The second protease we found to release
HBB(112–147) is Napsin A, a less explored aspartic protease
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present in the lung and kidney. While there is no description
of Napsin A being expressed in placental tissue in literature,
we detected Napsin A in placenta homogenate using specific
antibodies. Our findings suggest that a local acidification at sites
of infection or inflammation result in the rapid generation of
HBB(112–147) that acts as broad-based antibacterial (and anti-
HSV-2) agent.
The concentrations of HBB(112–147) that are required to
suppress HSV-2 infection or bacterial growth are in the high
µg/ml range. However, these seemingly high concentrations can
be readily achieved in vivo because the hemoglobin precursor
and the AMP-releasing protease are present almost everywhere
in the human body. Hemoglobin is the second most abundant
protein in humans with concentrations of 12–20 g in every 100 ml
of human blood, and 50 g in spleen and bone marrow. 15 g
of the tetrameric hemoglobin per 100 ml blood corresponds to
150 mg per 1 ml, and ∼75 mg of the β-hemoglobin subunits
per ml blood. Complete proteolytic processing of hemoglobin
(as it occurred in our in vitro digestions) would result in
concentrations of∼18 mg/ml of HBB(112–147). Even if only 10%
of available hemoglobin is digested, this would still correspond
to ∼1800 µg/ml, which is sufficient to block HSV-2 infection
or bacterial growth entirely. These theoretical considerations are
in line with experimental results obtained in previous studies
(Liepke et al., 2003; Ständker et al., 2010) that revealed HBB(112–
147) concentrations between 280 and 740 µg/g placenta tissue
in different placenta samples, corresponding to an average
concentration of 570 µg/g or ml. Thus, HBB(112–1476) may
represent the AMP with the highest reported concentration in a
human tissue and may play a key role in restricting transmission
of viral and bacterial pathogens across the placenta and perhaps
also other compartments.
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